OncoMatch/Clinical Trials/NCT05772390

Partial Breast Re-irradiation in Women in Women with Locally Recurrent Breast Cancer Previously Treated with Conservative Surgery and Whole Breast Irradiation

Is NCT05772390 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for breast cancer.

Phase 2RecruitingIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSNCT05772390Data as of Jun 2026Location: Italy

A prospective study of partial breast re-irradiation in patients with local recurrence of breast cancer

Extracted eligibility criteria

Cancer type

Breast Carcinoma

Biomarker criteria

Excluded: BRCA1 pathogenic mutation

Excluded: BRCA2 pathogenic mutation

Excluded: TP53 pathogenic mutation

Performance status

ECOG 0–1(Restricted strenuous activity)

Demographics

Female only

Prior therapy

Must have received: breast conserving therapy (surgery and whole breast radiotherapy)

≥ 24 months interval between initial breast conserving therapy (surgery and whole breast radiotherapy) and recurrence

Cannot have received: IORT, brachytherapy or previous partial breast treatment

Previous breast RT performed with IORT, brachytherapy or previous partial breast treatment

Cannot have received: chemotherapy

Exception: within 2 weeks prior to study RT

Patients who had chemotherapy within 2 weeks prior to study RT

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Is NCT05772390 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior IORT, brachytherapy or previous partial breast treatment, chemotherapy disqualifies patients from enrollment.

Are patients with BRCA1 alterations eligible?

No. BRCA1 pathogenic mutation is an exclusion criterion.

Are patients with BRCA2 alterations eligible?

No. BRCA2 pathogenic mutation is an exclusion criterion.

Is this trial open to male patients?

No. This trial enrolls female patients only.

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.